Temporal evolution of breast cancer brain metastases treatments and outcomes.

IF 6.5 2区医学 Q1 ONCOLOGY

NPJ Breast Cancer Pub Date : 2025-02-20 DOI:10.1038/s41523-025-00735-w

Michele Bottosso, Gaia Griguolo, Severine Guiu, Maria Cristina Guarascio, Caroline Bailleux, Federica Miglietta, Anna Chiara Cattelan, Christian Zurlo, Jean-Marc Ferrero, Vittoria Aldegheri, Cristina Falci, Francesca Zanghì, Carlo Alberto Giorgi, Alessandro Parisi, Grazia Maria Vernaci, Fabio Girardi, William Jacot, Maria Vittoria Dieci, Amélie Darlix, Valentina Guarneri

{"title":"Temporal evolution of breast cancer brain metastases treatments and outcomes.","authors":"Michele Bottosso, Gaia Griguolo, Severine Guiu, Maria Cristina Guarascio, Caroline Bailleux, Federica Miglietta, Anna Chiara Cattelan, Christian Zurlo, Jean-Marc Ferrero, Vittoria Aldegheri, Cristina Falci, Francesca Zanghì, Carlo Alberto Giorgi, Alessandro Parisi, Grazia Maria Vernaci, Fabio Girardi, William Jacot, Maria Vittoria Dieci, Amélie Darlix, Valentina Guarneri","doi":"10.1038/s41523-025-00735-w","DOIUrl":null,"url":null,"abstract":"<p><p>Brain metastases (BMs) are a common complication of advanced breast cancer (BC), and their management has significantly evolved. We evaluated the clinical impact of these changes dividing patients diagnosed with BCBMs at three Institutions according to year of BMs diagnosis: 2000-2007 (group A), 2008-2014 (group B) and 2015-2022 (group C). Stereotactic radiotherapy increased (p < 0.001), and WBRT decreased (p = 0.010) over time. Among HER2+ BC patients, more received anti-HER2 therapy after BM diagnosis in recent years (p < 0.011). Overall survival (OS) did not improve in the entire cohort (p = 0.260); however, OS improved in patients with HR-/HER2+ BC (median OS 8.7, 10.1, 23.7 months in group A, B, C, respectively; p = 0.002). HER2-positivity, not prognostic in group A, became prognostic in group C (p < 0.001). While therapy for patients with BCBMs significantly changed over two decades, an OS improvement was observed only in HR-/HER2+ patients, potentially due to increased availability of anti-HER2 therapies with intracranial activity.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"20"},"PeriodicalIF":6.5000,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11842824/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Breast Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41523-025-00735-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Brain metastases (BMs) are a common complication of advanced breast cancer (BC), and their management has significantly evolved. We evaluated the clinical impact of these changes dividing patients diagnosed with BCBMs at three Institutions according to year of BMs diagnosis: 2000-2007 (group A), 2008-2014 (group B) and 2015-2022 (group C). Stereotactic radiotherapy increased (p < 0.001), and WBRT decreased (p = 0.010) over time. Among HER2+ BC patients, more received anti-HER2 therapy after BM diagnosis in recent years (p < 0.011). Overall survival (OS) did not improve in the entire cohort (p = 0.260); however, OS improved in patients with HR-/HER2+ BC (median OS 8.7, 10.1, 23.7 months in group A, B, C, respectively; p = 0.002). HER2-positivity, not prognostic in group A, became prognostic in group C (p < 0.001). While therapy for patients with BCBMs significantly changed over two decades, an OS improvement was observed only in HR-/HER2+ patients, potentially due to increased availability of anti-HER2 therapies with intracranial activity.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

NPJ Breast Cancer Medicine-Pharmacology (medical)

CiteScore

10.10

自引率

1.70%

发文量

122

审稿时长

9 weeks

期刊介绍： npj Breast Cancer publishes original research articles, reviews, brief correspondence, meeting reports, editorial summaries and hypothesis generating observations which could be unexplained or preliminary findings from experiments, novel ideas, or the framing of new questions that need to be solved. Featured topics of the journal include imaging, immunotherapy, molecular classification of disease, mechanism-based therapies largely targeting signal transduction pathways, carcinogenesis including hereditary susceptibility and molecular epidemiology, survivorship issues including long-term toxicities of treatment and secondary neoplasm occurrence, the biophysics of cancer, mechanisms of metastasis and their perturbation, and studies of the tumor microenvironment.